147 related articles for article (PubMed ID: 35605657)
41. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
42. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
43. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
44. Neuroblastoma: Therapeutic strategies for a clinical enigma.
Modak S; Cheung NK
Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
[TBL] [Abstract][Full Text] [Related]
45. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
[TBL] [Abstract][Full Text] [Related]
46. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
47. Advancing therapy for neuroblastoma.
Qiu B; Matthay KK
Nat Rev Clin Oncol; 2022 Aug; 19(8):515-533. PubMed ID: 35614230
[TBL] [Abstract][Full Text] [Related]
48. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Chanthery YH; Gustafson WC; Itsara M; Persson A; Hackett CS; Grimmer M; Charron E; Yakovenko S; Kim G; Matthay KK; Weiss WA
Sci Transl Med; 2012 Jan; 4(115):115ra3. PubMed ID: 22218692
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
[TBL] [Abstract][Full Text] [Related]
50. Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.
Najem S; Langemann D; Appl B; Trochimiuk M; Hundsdoerfer P; Reinshagen K; Eschenburg G
Oncotarget; 2016 Nov; 7(45):72634-72653. PubMed ID: 27655666
[TBL] [Abstract][Full Text] [Related]
51. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
52. Stem cell transplantation for neuroblastoma.
Fish JD; Grupp SA
Bone Marrow Transplant; 2008 Jan; 41(2):159-65. PubMed ID: 18037943
[TBL] [Abstract][Full Text] [Related]
53. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
54. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
Matthay KK; O'Leary MC; Ramsay NK; Villablanca J; Reynolds CP; Atkinson JB; Haase GM; Stram DO; Seeger RC
Eur J Cancer; 1995; 31A(4):572-5. PubMed ID: 7576971
[TBL] [Abstract][Full Text] [Related]
55. Resistance to chemotherapeutic agents and promotion of transforming activity mediated by embryonic stem cell-expressed Ras (ERas) signal in neuroblastoma cells.
Aoyama M; Kataoka H; Kubota E; Tada T; Asai K
Int J Oncol; 2010 Oct; 37(4):1011-6. PubMed ID: 20811723
[TBL] [Abstract][Full Text] [Related]
56. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.
Venstrom JM; Zheng J; Noor N; Danis KE; Yeh AW; Cheung IY; Dupont B; O'Reilly RJ; Cheung NK; Hsu KC
Clin Cancer Res; 2009 Dec; 15(23):7330-4. PubMed ID: 19934297
[TBL] [Abstract][Full Text] [Related]
57. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
Megison ML; Stewart JE; Nabers HC; Gillory LA; Beierle EA
Clin Exp Metastasis; 2013 Jun; 30(5):555-68. PubMed ID: 23208732
[TBL] [Abstract][Full Text] [Related]
58. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
59. Advances in emerging drugs for the treatment of neuroblastoma.
Berlanga P; Cañete A; Castel V
Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
[TBL] [Abstract][Full Text] [Related]
60. Cell death-based treatment of neuroblastoma.
Valter K; Zhivotovsky B; Gogvadze V
Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
